442 related articles for article (PubMed ID: 36684555)
1. Transcription factors in the pathogenesis of pulmonary arterial hypertension-Current knowledge and therapeutic potential.
Körbelin J; Klein J; Matuszcak C; Runge J; Harbaum L; Klose H; Hennigs JK
Front Cardiovasc Med; 2022; 9():1036096. PubMed ID: 36684555
[TBL] [Abstract][Full Text] [Related]
2. New Drugs and Therapies in Pulmonary Arterial Hypertension.
Shah AJ; Beckmann T; Vorla M; Kalra DK
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982922
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension.
Chelladurai P; Kuenne C; Bourgeois A; Günther S; Valasarajan C; Cherian AV; Rottier RJ; Romanet C; Weigert A; Boucherat O; Eichstaedt CA; Ruppert C; Guenther A; Braun T; Looso M; Savai R; Seeger W; Bauer UM; Bonnet S; Pullamsetti SS
Sci Transl Med; 2022 Jun; 14(648):eabe5407. PubMed ID: 35675437
[TBL] [Abstract][Full Text] [Related]
4. Light at the ENDothelium-role of Sox17 and Runx1 in endothelial dysfunction and pulmonary arterial hypertension.
Simmons Beck R; Liang OD; Klinger JR
Front Cardiovasc Med; 2023; 10():1274033. PubMed ID: 38028440
[TBL] [Abstract][Full Text] [Related]
5. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
Orriols M; Gomez-Puerto MC; Ten Dijke P
Cell Mol Life Sci; 2017 Aug; 74(16):2979-2995. PubMed ID: 28447104
[TBL] [Abstract][Full Text] [Related]
6. Signal Mechanisms of Vascular Remodeling in the Development of Pulmonary Arterial Hypertension.
Li MX; Jiang DQ; Wang Y; Chen QZ; Ma YJ; Yu SS; Wang Y
J Cardiovasc Pharmacol; 2016 Feb; 67(2):182-90. PubMed ID: 26448276
[TBL] [Abstract][Full Text] [Related]
7. Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension.
Zolty R
J Exp Pharmacol; 2021; 13():817-857. PubMed ID: 34429666
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension.
Kim JD; Lee A; Choi J; Park Y; Kang H; Chang W; Lee MS; Kim J
Exp Mol Med; 2015 Jul; 47(7):e175. PubMed ID: 26228095
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of right ventricular dysfunction in pulmonary arterial hypertension: focus on the coronary vasculature, sex hormones, and glucose/lipid metabolism.
Agrawal V; Lahm T; Hansmann G; Hemnes AR
Cardiovasc Diagn Ther; 2020 Oct; 10(5):1522-1540. PubMed ID: 33224772
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Targets for Oligonucleotide Therapies of Pulmonary Arterial Hypertension.
Gerthoffer W
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287230
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary artery banding is a relevant model to study the right ventricular remodeling and dysfunction that occurs in pulmonary arterial hypertension.
Akazawa Y; Okumura K; Ishii R; Slorach C; Hui W; Ide H; Honjo O; Sun M; Kabir G; Connelly K; Friedberg MK
J Appl Physiol (1985); 2020 Aug; 129(2):238-246. PubMed ID: 32644912
[TBL] [Abstract][Full Text] [Related]
12. Cellular interplay in pulmonary arterial hypertension: implications for new therapies.
Nogueira-Ferreira R; Ferreira R; Henriques-Coelho T
Biochim Biophys Acta; 2014 May; 1843(5):885-93. PubMed ID: 24491811
[TBL] [Abstract][Full Text] [Related]
13. Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2α.
Dai Z; Li M; Wharton J; Zhu MM; Zhao YY
Circulation; 2016 Jun; 133(24):2447-58. PubMed ID: 27143681
[TBL] [Abstract][Full Text] [Related]
14. Pathological Mechanisms and Potential Therapeutic Targets of Pulmonary Arterial Hypertension: A Review.
Xiao Y; Chen PP; Zhou RL; Zhang Y; Tian Z; Zhang SY
Aging Dis; 2020 Dec; 11(6):1623-1639. PubMed ID: 33269111
[TBL] [Abstract][Full Text] [Related]
15. Glutaminolysis: A Driver of Vascular and Cardiac Remodeling in Pulmonary Arterial Hypertension.
Mprah R; Adzika GK; Gyasi YI; Ndzie Noah ML; Adu-Amankwaah J; Adekunle AO; Duah M; Wowui PI; Weili Q
Front Cardiovasc Med; 2021; 8():667446. PubMed ID: 33996951
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
Ruopp NF; Cockrill BA
JAMA; 2022 Apr; 327(14):1379-1391. PubMed ID: 35412560
[TBL] [Abstract][Full Text] [Related]
17. FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension.
Bourgeois A; Lambert C; Habbout K; Ranchoux B; Paquet-Marceau S; Trinh I; Breuils-Bonnet S; Paradis R; Nadeau V; Paulin R; Provencher S; Bonnet S; Boucherat O
J Mol Med (Berl); 2018 Feb; 96(2):223-235. PubMed ID: 29290032
[TBL] [Abstract][Full Text] [Related]
18. LncRNA-SMILR modulates RhoA/ROCK signaling by targeting miR-141 to regulate vascular remodeling in pulmonary arterial hypertension.
Lei S; Peng F; Li ML; Duan WB; Peng CQ; Wu SJ
Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H377-H391. PubMed ID: 32559140
[TBL] [Abstract][Full Text] [Related]
19. [Female gender and pulmonary arterial hypertension: a complex relationship].
Manes A; Palazzini M; Dardi F; D'Adamo A; Rinaldi A; Galiè N
G Ital Cardiol (Rome); 2012 Jun; 13(6):448-60. PubMed ID: 22622125
[TBL] [Abstract][Full Text] [Related]
20. Purinergic Dysfunction in Pulmonary Arterial Hypertension.
Cai Z; Tu L; Guignabert C; Merkus D; Zhou Z
J Am Heart Assoc; 2020 Sep; 9(18):e017404. PubMed ID: 32867554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
